Who owns ALNYLAM PHARMACEUTICALS INC NOTE 1.000 9/1?
- CUSIP Number: 02043qab3
Tip: Access positions for across all investors
Analyze quarterly positions in Alnylam Pharmaceuticals Inc Note 1.000 9/1 with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Alnylam Pharmaceuticals Inc Note 1.000 9/1 stock
Who bought or sold ALNYLAM PHARMACEUTICALS INC NOTE 1.000 9/1 this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Steelhead Partners | 65M | $78B | 8% | Jun 2026 |
|
| Bnp Paribas Arbitrage, Snc | 42M | $51M | 31% | Jun 2026 |
|
| Alberta Investment Management Corporation | 25M | $30M | 0% | Jun 2026 |
|
| DeepCurrents Investment Group | 24M | $29M | 0% | Jun 2026 |
|
| State Street Corporation | 23M | $29M | 4% | Mar 2026 |
|
| Bank of America Corporation | 19M | $23M | 72% | Jun 2026 |
|
| FMR | 17M | $21M | -7% | Jun 2026 |
|
| MacKay Shields | 15M | $18M | 0% | Jun 2026 |
|
| Manufacturers Life Insurance Company | 14M | $17M | 0% | Jun 2026 |
|
| Universal- Beteiligungs- und Servicegesellschaft mbH | 11M | $13M | 28% | Jun 2026 |
|
| Bnp Paribas Investment Partners | 9.6M | $11M | -2% | Jun 2026 |
|
| CSS | 9.1M | $11M | -51% | Jun 2026 |
|
| Ameriprise Financial | 8.9M | $11M | 100% | Jun 2026 |
|
| BlackRock | 8.0M | $9.6M | -52% | Jun 2026 |
|
| Toronto-Dominion Bank | 6.5M | $7.8M | 100% | Jun 2026 |
|
| Citigroup | 5.7M | $7.2M | 100% | Mar 2026 |
|
| Zazove Associates | 5.1M | $6.1M | 100% | Jun 2026 |
|
| Warberg Asset Management | 5.0M | $6.0M | 0% | Jun 2026 |
|
| Amundi | 5.0M | $6.0M | 0% | Jun 2026 |
|
| SSI Investment Management | 4.1M | $4.9M | 0% | Jun 2026 |
|
| Jpmorgan Chase & Co | 3.2M | $3.8M | 100% | Jun 2026 |
|
| Morgan Stanley | 3.1M | $4.0M | 2500% | Mar 2026 |
|
| EFG International | 3.0M | $3.6M | 50% | Jun 2026 |
|
| Franklin Resources | 2.2M | $2.7M | 0% | Jun 2026 |
|
| Union Bancaire Privee, UBP SA | 2.1M | $2.2M | 8% | Jun 2026 |
|
| Nomura Asset Management International | 2.1M | $2.5M | -1% | Jun 2026 |
|
| Invesco | 1.5M | $1.8M | -40% | Jun 2026 |
|
| Barclays | 1.3M | $1.5M | 100% | Jun 2026 |
|
| Kim | 1.0M | $1.2M | 0% | Jun 2026 |
|
| Agf Management | 950k | $1.1M | 0% | Jun 2026 |
|
| Advent Capital Management | 850k | $1.0M | 100% | Jun 2026 |
|
| Wells Fargo & Company | 664k | $799k | -27% | Jun 2026 |
|
| Zurcher Kantonalbank | 400k | $478k | 100% | Jun 2026 |
|
| Goldman Sachs Group | 374k | $450k | 0% | Jun 2026 |
|
| Sei Investments | 251k | $302k | 0% | Jun 2026 |
|
| Central Pacific Bank - Trust Division | 224k | $269k | 0% | Jun 2026 |
|
| Bank of New York Mellon | 215k | $259k | 0% | Jun 2026 |
|
| Virtus Fixed Income Advisers | 161k | $194k | 100% | Jun 2026 |
|
| Oppenheimer Asset Management | 80k | $96k | -1% | Jun 2026 |
|
| Virtus ETF Advisers | 36k | $43k | 0% | Jun 2026 |
|
| Boussard & Gavaudan Investment Management | 32k | $41M | 53% | Mar 2026 |
|
| LPL Financial | 31k | $37k | 100% | Jun 2026 |
|
| Stephens | 24k | $29k | 0% | Jun 2026 |
|
| UBS Group | 23k | $28k | 1% | Jun 2026 |
|
| Alken Asset Management | 1.6k | $1.9M | 60% | Jun 2026 |
|
| Steward Partners Investment Advisory | 1.0k | $1.2k | 0% | Jun 2026 |
|
Who sold out of Alnylam Pharmaceuticals Inc Note 1.000 9/1?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Two Sigma Investments | Mar 2026 | 6.0M | $7.7M |
| Lord, Abbett & Co | Mar 2026 | 1.2M | $1.5M |
| Leucadia National Corporation | Mar 2026 | 681k | $874k |
| Balboa Wealth Partners | Mar 2026 | 14k | $18k |
| Mml Investors Services | Mar 2026 | 10k | $13k |
| Loomis, Sayles and | Mar 2026 | 4.9k | $1.6M |
| Royal Bank of Canada | Mar 2026 | 2.0k | $3.0k |
| Us Bancorp | Dec 2025 | 2.0k | $2.9k |